# DR.NOAH BIOTECH

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dr-noah-biotech

- Industry: Biotechnology
- Headquarters: Suwon, South Korea
- Website: www.drnoahbiotech.com
- Total disclosed funding: $15M
- Latest round: Series B (Jun 17, 2022)
- Investors on record: 10

## About

Based in South Korea, Dr. Noah Biotech specializes in developing innovative drug candidates, focusing on complex drug combinations for orphan diseases using advanced AI technologies.Founded in 2016, Dr. Noah Biotech operates out of Suwon, South Korea and is dedicated to advancing drug development for orphan diseases through its innovative AI-driven platforms. The company has successfully raised a total of KRW 13.9 billion, securing Series B funding on June 17, 2022, from various investors, including CKD Venture Capital and Korea Venture Investment Corporation. Ji-hyun Lee serves as CEO.Dr. Noah Biotech specializes in the development of innovative drug candidates, particularly focusing on complex drug combinations aimed at treating orphan diseases. Their core offerings include an AI-based platform known as the ARK system, which comprises multiple solutions for drug repositioning and synergistic combination therapies. The platform leverages extensive bio-pharmacological data to identify potential drug candidates, reducing clinical trial failure rates related to safety and efficacy. The company collaborates with global partners across diverse geographical markets, including North America and Europe, to enhance its research and development capabilities. Their products are designed for healthcare institutions and pharmaceutical companies, ultimately targeting patients with limited treatment options for rare diseases.Dr. Noah Biotech generates revenue primarily through strategic partnerships and collaborations with international pharmaceutical companies and research institutions. The transaction structure typically involves B2B agreements, where the company provides its AI-driven drug discovery services in exchange for service fees or milestone payments tied to the development progress of drug candidates. These partnerships often include contracts that allow for revenue sharing based on the successful commercialization of developed therapies. The company’s flagship offerings, such as the Multi-Strategy Drug Repositioning System, are integrated into long-term agreements with clients aiming to enhance their drug development pipelines.In June 2022, Dr. Noah Biotech raised KRW 13.9 billion in Series B funding, which will be utilized to support product clinical trials in the U.S. and the upcoming pipelines of preclinical trials. The company plans to expand its market presence into additional regions, focusing on North America and Europe, with specific initiatives aimed for completion by 2024. Through these efforts, Dr. Noah Biotech aims to enhance its capabilities in drug development and better serve patients with orphan diseases.

## Funding rounds

- Series B, Jun 17, 2022, $11M — CKD Venture Capital, Yuanta Investment, L&S Venture Capital, Pathfinder H, Ingradient, Inc., Korea Venture Investment Corporation
- Series A, Aug 12, 2020, $3.8M — KB Investment, Posco Investment, BNH Investment, T Investment

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series A
- BNH Investment (https://capitalatlas.ai/funds/bnh-investment) — Series A
- T Investment (https://capitalatlas.ai/funds/t-investment) — Series A
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series B
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series B
- L&S Venture Capital (https://capitalatlas.ai/funds/l-s-venture-capital) — Series B
- Pathfinder H (https://capitalatlas.ai/funds/pathfinder-h) — Series B
- Ingradient, Inc. — Series B
- Korea Venture Investment Corporation (https://capitalatlas.ai/funds/korea-venture-investment-corporation) — Series B